Literature DB >> 19949919

Studying drug resistance using genetically engineered mouse models for breast cancer.

Sven Rottenberg1, Marina Pajic, Jos Jonkers.   

Abstract

The generation of genetically engineered mouse models (GEMMs) that mimic breast cancer in humans provides new tools to investigate mechanisms of drug resistance in vivo. The advantages are manifold: inbred mice do not have the genomic heterogeneity seen in patients; mammary tumors are superficial and therefore easily accessible for measurement and sampling pre- and posttreatment; tumors can be transplanted orthotopically into syngeneic, immunocompetent animals; and tumor cells can be modified in vitro (e.g., gene overexpression, shRNA knockdown, insertional mutagenesis) prior to transplantation. Here, we provide an overview with experimental details of various approaches to study mechanisms of drug resistance in GEMMs for breast cancer.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19949919     DOI: 10.1007/978-1-60761-416-6_3

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  6 in total

1.  In situ CRISPR-Cas9 base editing for the development of genetically engineered mouse models of breast cancer.

Authors:  Stefano Annunziato; Catrin Lutz; Linda Henneman; Jinhyuk Bhin; Kim Wong; Bjørn Siteur; Bas van Gerwen; Renske de Korte-Grimmerink; Maria Paz Zafra; Emma M Schatoff; Anne Paulien Drenth; Eline van der Burg; Timo Eijkman; Siddhartha Mukherjee; Katharina Boroviak; Lodewyk Fa Wessels; Marieke van de Ven; Ivo J Huijbers; David J Adams; Lukas E Dow; Jos Jonkers
Journal:  EMBO J       Date:  2020-01-13       Impact factor: 11.598

2.  Tumor-initiating cells are not enriched in cisplatin-surviving BRCA1;p53-deficient mammary tumor cells in vivo.

Authors:  Marina Pajic; Ariena Kersbergen; Frank van Diepen; Anita Pfauth; Jos Jonkers; Piet Borst; Sven Rottenberg
Journal:  Cell Cycle       Date:  2010-09-13       Impact factor: 4.534

Review 3.  Studying therapy response and resistance in mouse models for BRCA1-deficient breast cancer.

Authors:  Ewa Malgorzata Michalak; Jos Jonkers
Journal:  J Mammary Gland Biol Neoplasia       Date:  2011-02-18       Impact factor: 2.673

4.  Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance.

Authors:  Elizabeth S Nakasone; Hanne A Askautrud; Tim Kees; Jae-Hyun Park; Vicki Plaks; Andrew J Ewald; Miriam Fein; Morten G Rasch; Ying-Xim Tan; Jing Qiu; Juwon Park; Pranay Sinha; Mina J Bissell; Eirik Frengen; Zena Werb; Mikala Egeblad
Journal:  Cancer Cell       Date:  2012-04-17       Impact factor: 31.743

Review 5.  Genetically engineered mouse models of PI3K signaling in breast cancer.

Authors:  Sjoerd Klarenbeek; Martine H van Miltenburg; Jos Jonkers
Journal:  Mol Oncol       Date:  2013-02-11       Impact factor: 6.603

Review 6.  Patient-derived xenograft (PDX) models in basic and translational breast cancer research.

Authors:  Lacey E Dobrolecki; Susie D Airhart; Denis G Alferez; Samuel Aparicio; Fariba Behbod; Mohamed Bentires-Alj; Cathrin Brisken; Carol J Bult; Shirong Cai; Robert B Clarke; Heidi Dowst; Matthew J Ellis; Eva Gonzalez-Suarez; Richard D Iggo; Peter Kabos; Shunqiang Li; Geoffrey J Lindeman; Elisabetta Marangoni; Aaron McCoy; Funda Meric-Bernstam; Helen Piwnica-Worms; Marie-France Poupon; Jorge Reis-Filho; Carol A Sartorius; Valentina Scabia; George Sflomos; Yizheng Tu; François Vaillant; Jane E Visvader; Alana Welm; Max S Wicha; Michael T Lewis
Journal:  Cancer Metastasis Rev       Date:  2016-12       Impact factor: 9.264

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.